Viewing data from:

ALVAIZ

NDA

ELTROMBOPAG CHOLINE | N216774 | TEVA PHARMACEUTICALS INC

4 strengths1 unique patent0 unique exclusivities

Patent Timeline

1 unique patent by expiration date

Active (1)Today

2026

2027

2028

2029

2030

2031

2032

2033

2034

2035

2036

2037

2038

2039

Today

11072586

Nov. 5, 2038

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

API Supply Chain1 active DMF

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

TAPI NL BVELTROMBOPAG CHOLINE

DMF 355202021

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Jan 20, 2026	SUPPL -6	View Letter (PDF)
Nov 29, 2023	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (4)

Sort:

#001 — EQ 9MG BASE

RLD

1 patent0 exclusivities▴

TABLET;ORAL | Approved: Nov 29, 2023

Patents (1)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
11072586	Nov 5, 2038	—	Yes	Yes		—

#002 — EQ 18MG BASE

RLD

1 patent0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2023

#003 — EQ 36MG BASE

RLD

1 patent0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2023

#004 — EQ 54MG BASE

RLD

1 patent0 exclusivities▾

TABLET;ORAL | Approved: Nov 29, 2023